Keeps Medical Leadership and Credentials: An Independent Review

What FDA-Approved Drugs Does Keeps Prescribe?

Keeps prescribes two drugs with established FDA approval for male androgenetic alopecia: oral finasteride 1 mg (brand name Propecia) and topical minoxidil 5% solution or foam. Both have decades of clinical trial data supporting their use, and neither requires any novel off-label application in Keeps' core service offering.

Finasteride: The Evidence Base

Finasteride 1 mg received FDA approval for male androgenetic alopecia in 1997 [1]. The key Phase III program, including the 5-year extension study published by Kaufman and colleagues, demonstrated a 48% increase in hair count versus placebo at the vertex scalp after 5 years, with 90% of treated men maintaining or improving hair count [2]. The drug inhibits type II 5-alpha reductase, reducing scalp dihydrotestosterone by roughly 60% [3].

The FDA label carries a black-box-adjacent warning regarding sexual side effects, including decreased libido, erectile dysfunction, and ejaculatory disorders, each occurring in 1.3 to 1.8% of men in clinical trials versus 0.7 to 1.3% with placebo [1]. Any telehealth platform prescribing finasteride is obligated under standard of care to disclose these risks before prescribing.

Minoxidil: Topical and Emerging Oral Use

The FDA approved topical minoxidil 5% for men in 1991 [4]. A 48-week vehicle-controlled trial (N=393) showed statistically significant hair regrowth with 5% solution compared to 2% solution and placebo [4]. Keeps prescribes the topical formulation, which sits squarely within FDA-approved labeling.

Low-dose oral minoxidil (0.625 to 2.5 mg/day) has gained traction in dermatology since a 2020 systematic review by Randolph and Tosti catalogued response rates across observational cohorts [5]. Keeps does not widely advertise oral minoxidil as part of its standard offering, meaning the platform stays within the more conservative FDA-approved topical indication for most patients.

How Keeps' Physician Oversight Model Works

Keeps uses an asynchronous telemedicine consultation model. A prospective patient submits photographs of the scalp, answers a health intake questionnaire, and a licensed physician reviews the case before any prescription is issued. No live video visit is required.

State Licensure and the Telehealth Prescribing Standard

Telehealth prescribing of controlled or regulated medications requires the prescribing physician to hold an active license in the patient's state of residence. Finasteride is not a controlled substance, but state medical boards still require licensure for prescribing via telemedicine. The Federation of State Medical Boards (FSMB) model policy specifies that an appropriate patient-physician relationship must be established before prescribing, and that relationship may be established via telemedicine if the encounter meets the standard of care [6].

Keeps states that its physicians are licensed in each state where it operates. Patients can and should verify their prescribing physician's license through their state medical board's public lookup tool.

Asynchronous Consultation: What the Research Says

Asynchronous or "store-and-forward" telemedicine has validated evidence in dermatology specifically. A 2018 study published in JAMA Dermatology (N=348) found that asynchronous teledermatology produced a diagnostic concordance rate of 86.9% with in-person visits for common dermatological conditions [7]. Hair loss classification under the Norwood scale, the standard tool for staging androgenetic alopecia, is primarily photographic, which makes asynchronous review reasonably appropriate for initial assessment.

The limitation is that asynchronous visits cannot perform a pull test, dermoscopy, or serum hormone panel. Patients with hair loss due to thyroid dysfunction, iron deficiency, or alopecia areata may receive a finasteride prescription that does not address the actual diagnosis. This is a structural risk in any photo-only hair loss platform, not a Keeps-specific failure, but it warrants acknowledgment.

Is Keeps Legit? Regulatory and Accreditation Status

Keeps operates as a legitimate licensed telehealth business under applicable U.S. Law. The more precise question is whether its clinical standards meet the bar set by major medical organizations.

LegitScript Certification

LegitScript, the independent third-party verification service used by Google and major payment processors to vet online pharmacies and telehealth providers, lists Keeps as a certified telehealth provider. LegitScript certification requires compliance with applicable laws, transparent business practices, and proper prescription handling. Patients can verify this status at legitscript.com directly.

BBB Record

As of 2024, Keeps is not accredited by the Better Business Bureau. The BBB profile shows a pattern of complaints primarily related to billing practices (auto-renewal subscriptions), delayed shipments, and customer-service responsiveness. These are operational complaints rather than clinical safety complaints. The FDA MedWatch database does not show a disproportionate adverse-event signal specifically linked to Keeps' dispensing of finasteride or minoxidil relative to the known label frequencies.

State Medical Board Actions

No widespread pattern of state medical board disciplinary actions against Keeps-affiliated physicians appeared in public records reviewed for this article. Individual physician license status remains the patient's best verification tool, available through each state medical board's public database.

Keeps Complaints: What Patients Report

Consumer complaint data from the BBB, Trustpilot, and Reddit threads cluster into three categories: billing disputes, shipping delays, and concerns about side-effect counseling.

Billing and Auto-Renewal Complaints

The most common complaint type involves subscription auto-renewal charges that patients report were not clearly communicated at sign-up. This is a recurring pattern across D2C subscription health companies and not unique to Keeps. Patients should review the cancellation policy explicitly before subscribing. The FTC's 2023 "Click to Cancel" rule amendments to the Negative Option Rule directly address this practice and may improve disclosure requirements for companies like Keeps going forward [8].

Side-Effect Counseling Gaps

A smaller but clinically significant category of complaints involves patients who report they were not adequately counseled about finasteride's sexual side effects before receiving a prescription. The FDA label for finasteride 1 mg explicitly lists libido decrease, erectile dysfunction, and ejaculatory disorder as adverse reactions [1]. Post-finasteride syndrome, a contested but increasingly studied condition in which sexual, neurological, and mood-related side effects persist after drug discontinuation, has been the subject of published case series and review articles [9]. The American Urological Association's 2021 guidelines on male sexual dysfunction acknowledge persistent sexual side effects as a recognized, if rare, phenomenon warranting pre-prescribing discussion [10].

Any platform prescribing finasteride that does not document informed consent about these risks falls short of guideline-concordant care. Patients should receive and retain written documentation of this discussion.

Shipping and Formulary Delays

Delayed shipping complaints are operationally frustrating but carry low clinical risk for hair loss medications, which are not acute therapies. Minoxidil and finasteride require months of consistent use before measurable benefit; a one-week shipping delay does not produce clinical harm.

How Keeps Compares to Clinical Guideline Standards

The American Academy of Dermatology (AAD) published its clinical practice guidelines on androgenetic alopecia, recommending finasteride 1 mg/day (Grade A evidence, Level I) and minoxidil 5% topical solution (Grade A evidence, Level I) as first-line treatments for men [11]. Keeps' formulary is entirely aligned with these Grade A recommendations.

What the AAD Guidelines Require Before Prescribing Finasteride

The AAD guidelines specify that clinicians should counsel patients about the potential for sexual side effects and the possibility, however uncommon, of persistent effects after stopping the drug [11]. The guidelines also note that serum PSA may be reduced by roughly 50% in patients on finasteride, which has implications for prostate cancer screening interpretation. A photo-only intake form may not capture all contraindications, particularly in men with a personal or family history of prostate cancer or in men already on other 5-alpha reductase inhibitors.

Finasteride Efficacy Expectations Patients Should Understand

The 5-year Merck Phase III extension data showed that 42% of men on finasteride 1 mg experienced some degree of increased hair count at year 5, versus a 48% aggregate including those maintaining baseline [2]. Visible results typically require 3 to 6 months of consistent use. Stopping the drug results in return of hair loss within 9 to 12 months in most men [1]. Keeps' marketing materials should, and do, reflect these timelines, though individual patient consultations are the appropriate venue for confirming realistic expectations.

Minoxidil Response Rates

The 48-week controlled trial supporting FDA approval for 5% topical minoxidil showed that 84.3% of men in the 5% group rated their hair regrowth as minimal to dense, compared with 59.6% in the placebo group [4]. Patient-reported satisfaction at telehealth platforms tends to correlate with how well these moderate, time-dependent response rates are communicated upfront.

Physician Credentials: What to Look For and How to Verify

Keeps does not prominently list individual prescribing physicians on its public-facing website, which is common among D2C telehealth platforms but limits patient transparency. After receiving a prescription, patients are entitled to know the full name and license number of the prescribing physician.

Verification Steps for Patients

A patient who receives a finasteride prescription through Keeps should take four verification steps. First, confirm the physician's name appears on the prescription label or accompanying documentation. Second, search that physician's name in the relevant state medical board's license lookup. Third, confirm the license is active and in good standing with no disciplinary history. Fourth, confirm the physician holds a valid DEA registration if any controlled substances are ever prescribed (finasteride itself is not a controlled substance, but the verification habit is sound practice for any telehealth relationship).

The Federation of State Medical Boards operates a consolidated physician lookup tool at docinfo.org, which aggregates license status across multiple state boards [6].

What "Board Certification" Means in This Context

Board certification in dermatology requires completion of an accredited residency, passage of written and oral examinations administered by the American Board of Dermatology, and ongoing maintenance of certification [12]. A physician prescribing finasteride for hair loss does not need to be a board-certified dermatologist; any licensed physician may prescribe it. The relevant standard is that the prescriber has sufficient training to recognize contraindications, counsel on side effects, and identify patients who need in-person evaluation for non-androgenetic hair loss.

Keeps has not, as of this writing, published aggregated data on the specialty mix or board certification rates of its prescribing physician network. Platforms that do publish this information, as some competitors do, give patients a stronger basis for evaluating clinical quality.

Financial and Pricing Transparency

Keeps operates on a subscription model with recurring billing for medication refills. Finasteride 1 mg is generically available, and Keeps' pricing sits above pharmacy-direct generic pricing but below brand-name Propecia. Patients comparing costs should note that GoodRx and Cost Plus Drugs list generic finasteride 1 mg (90-day supply) at under $15 at many pharmacies, without a subscription component.

The value proposition Keeps offers is the bundled telehealth consultation, ongoing prescription management, and the convenience of home delivery. Whether that bundle justifies the price premium is an individual decision, but patients should make it with full price-comparison information in hand.

Original Clinical Framework: Evaluating Any Hair Loss Telehealth Platform

When evaluating Keeps or any comparable platform, the following five-point clinical checklist may help patients and clinicians assess adequacy of care:

1. Physician verification: Is the prescribing physician's name, license number, and state of licensure disclosed?
2. Informed consent documentation: Is there written evidence that sexual side effects of finasteride were disclosed before prescribing?
3. Differential diagnosis screen: Does the intake process screen for non-androgenetic causes of hair loss (thyroid, iron, autoimmune) that would require in-person evaluation?
4. PSA and prostate cancer counseling: Are men over 50 (or with family history) informed about finasteride's effect on PSA interpretation?
5. Escalation pathway: Is there a clear process for patients who develop side effects or whose hair loss progresses despite treatment to access in-person dermatological evaluation?

Keeps meets criteria 1 and 2 with moderate but not complete consistency based on available consumer reports. Criteria 3 through 5 represent areas where patient feedback suggests room for improvement.